Home LiteratureArticle Details
PMID: 8573621 Published · ppublish English Clinical Trial Controlled Clinical Trial Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector.

Human gene therapy ·Vol. 6 ·No. 11 ·1995-11-00 ·Pages 1487-96

Hay JG, McElvaney NG, Herena J, Crystal RG

Abstract

Mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR) manifest on the nasal epithelial surface of individuals with cystic fibrosis (CF) by Na+ hyperabsorption and diminished beta-agonist-induced Cl- conductance, resulting in an abnormal bioelectric phenotype across the nasal epithelium. A clinical trial was conducted to determine if a replication-deficient, recombinant adenovirus vector containing a normal copy of the CFTR cDNA (AdCFTR) could, when administered to the nasal epithelium, correct the abnormal bioelectric phenotype. Nine individuals with CF received 2 x 10(5) to 2 x 10(8.5) plaque forming units of AdCFTR to the epithelium of one nostril. Measurements made included: baseline electrical potential difference (PD) between the surface of the nasal epithelium and the interstitial fluid, change in PD in response to amiloride, which inhibits apical Na+ channels, and change in PD in response to isoproterenol in a low Cl- solution, a measure of cAMP-regulated Cl- conductance. The functional integrity of the epithelium was evaluated by the PD response to ATP. Each individual served as their own control with measurements made in the nostril to be treated before AdCFTR administration, and in the contralateral untreated nostril. On the average, in the treated nostril over 2 weeks after the local administration of the adenovirus vector compared to measurements made in the same nostril before treatment, baseline PD decreased toward normal (-53.3 +/- 4.0 to -34.6 +/- 3.4, p = 0.01), response to amiloride decreased toward normal (36.9 +/- 4.7 to 19.7 +/- 3.0, p = 0.02), and response to low Cl- and isoproterenol increased toward normal (-4.5 +/- 1.5 to -9.1 +/- 2.1, p = 0.05). There were no changes in response to ATP (-15.3 +/- 2.7 to -15.8 +/- 1.9, p = 0.39), suggesting that the epithelium remained functionally intact. Importantly, there were no significant changes in measurements made in the untreated nostril. While limited to the nasal epithelium, these data suggest an adenovirus vector can safely deliver sufficient CFTR cDNA function to improve the abnormal CF bioelectric phenotype.

MeSH Terms
Adenoviridae/genetics Administration, Intranasal Adult Chlorides/metabolism Cystic Fibrosis/physiopathology,therapy Cystic Fibrosis Transmembrane Conductance Regulator/genetics,therapeutic use DNA, Complementary Epithelium Female Gene Transfer Techniques Genetic Therapy Genetic Vectors Humans Male Membrane Potentials Nasal Cavity/drug effects,physiology Phenotype Sodium/metabolism
Chemicals
CFTR protein, human Chlorides DNA, Complementary Cystic Fibrosis Transmembrane Conductance Regulator Sodium
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Hay J G
Division of Pulmonary and Critical Care Medicine, New York Hospital-Cornell Medical Center, NY 10021, USA.
McElvaney N G
Herena J
Crystal R G
Article Info
Journal
Human gene therapy
Abbr.
Hum Gene Ther
ISSN
1043-0342
Published
1995-11-00
Pages
1487-96
Language
English
Region
United States
NLM ID
9008950
Subset
IM
Grants
NCRR NIH HHS · M01-RR00047-33 · United States
NCRR NIH HHS · M01-RR00102-30 · United States
NHLBI NIH HHS · P01 HL51746-01 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]